High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Ann Oncol. 2010 May:21 Suppl 5:v190-3. doi: 10.1093/annonc/mdq187.

Authors

R Stupp¹, J-C Tonn, M Brada, G Pentheroudakis; ESMO Guidelines Working Group

Affiliation

¹ Centre Hospitalier Universitaire Vaudois, University of Lausanne, Switzerland.

PMID: 20555079
DOI: 10.1093/annonc/mdq187

No abstract available

Publication types

Practice Guideline
Research Support, Non-U.S. Gov't

MeSH terms

Adrenal Cortex Hormones / therapeutic use
Antineoplastic Agents, Alkylating / therapeutic use
Brain Neoplasms / diagnosis*
Brain Neoplasms / pathology
Brain Neoplasms / therapy*
Dacarbazine / analogs & derivatives
Dacarbazine / therapeutic use
Europe / epidemiology
Follow-Up Studies
Genetic Markers
Glioma / diagnosis*
Glioma / genetics
Glioma / pathology
Glioma / therapy*
Humans
Incidence
Loss of Heterozygosity
Neoplasm Staging
Prognosis
Radiotherapy
Randomized Controlled Trials as Topic
Risk Assessment
Secondary Prevention
Temozolomide
Treatment Outcome

Substances

Adrenal Cortex Hormones
Antineoplastic Agents, Alkylating
Genetic Markers
Dacarbazine
Temozolomide